Development of In-Vitro Assays to Assess the Potency of Botulinum Neurotoxin Type A (STTR [R41/R42])
ArchivedNational Institutes of Health
Description
Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose to develop new non-animal-based assays to assess the potency of botulinum neurotoxin type A (BoNT/A) in a Good Manufacturing Practice (GMP) commercial environment. Successful projects should have as their goal the development of a test(s) and reagents that could be used for commercial release testing of BoNT/A products. Mechanism of Support. This FOA will utilize the STTR (R41/R42) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-179, which encourages applications under the Small Business Innovation Research (SBIR) (R43/R44) grant mechanisms. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.
Who can apply
- Small businesses
Contact
NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV
- PostedApr 29, 2009
- ClosesMay 7, 2012
- CFDA93.103, 93.853
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro